Recap: Syneos Health Q1 Earnings

Shares of Syneos Health SYNH remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share increased 16.18% over the past year to $0.79, which beat the estimate of $0.75.

Revenue of $1,209,000,000 up by 3.96% year over year, which beat the estimate of $1,190,000,000.

Guidance

Syneos Health raised FY21 adjusted EPS guidance from $4.09-$4.38 to $4.17-$4.42.

The company reaffirmed sales guidance of $5.125B-$5.325B .

Details Of The Call

Date: Apr 29, 2021

Time: 08:00 AM

ET Webcast URL: https://www.directeventreg.com/der/toRegistration.action

Price Action

Company's 52-week high was at $89.95

52-week low: $50.27

Price action over last quarter: Up 15.38%

Company Description

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.